益钙宁治疗骨质疏松症骨痛45例疗效观察  

45 CASES OF PRIMARY OSTEOPOROSIS PATIENTS TREATED WITH ELCATONIN

作　　者：孟迅吾[1] 邢小平[1] 周学瀛[1] 陈莉[1] 孔彦平[1] 刘书勤[1] 刘怀成[1] 史轶蘩[1] 余卫[2] 

机构地区：[1]北京协和医院内分泌科,100730 [2]北京协和医院放射科,100730

出　　处：《中华内分泌代谢杂志》1993年第3期155-157,共3页Chinese Journal of Endocrinology and Metabolism

摘　　要：益钙宁(人工合成鳗鱼降钙素,Elcatonin)治疗原发性骨质疏松症45例,有明显的减轻骨痛和改善活动功能的效果,有效率为91.1％,31例(占68.9％)病人停药后改善疼痛作用持续1个月以上。血TRAP和尿Ftyp排量在用约后均有明显降低,支持此药行抑制破骨细胞活性的作用。仅用药初期少数病人有轻微脸红、心悸或恶心等副作用。可自行缓解或对症处理后消失。45 cases (female 43, male 2 ) of primary osteoporosis patients, average age 65.2±7.5 years, treated with Elcatonin by intramuscular injection 10 U each time, twice a week for four weeks. 63.9%- 80.0% of the patients had shown improvement in various symptoms of osteoporosis. Analgesic effect appeared 2 weeks later and became obvious after 3 weeks of treatment. This effect persisted for more than one month on 68.9% patients after withdrawal of Elcatonin. The mean values of serum TRAP and urinary hydroxyproline decreased significantly from 9.8 IU/ L to 8.4 IU / L (P< 0.01) and from 26.5 mg/24h to 19.7 mg/24h (P<0.01) respectively. The side effects were mild and negligible. The rate of effectiveness was 91.9%. Our conclusion is that Elcatonin is a safe and effective remedy for relief of bone pain and for suppressing the activity of osteoclasts in osteoporosis patients.

关 键 词：益钙宁 骨质松症 羟脯氨酸 疗效 

分 类 号：R681[医药卫生—骨科学]